OpenEvidence

Active#1 worldwide · Clinical software

Clinical software

HQUnited States

Last roundEquity round · Sep 2026

Uback rankings

Ranking	Tier	Rank	Edition	Next update
Clinical software · worldwide	Top 14	#1	Edition 0 (beta) · Sep 2026	22 Feb 2027

Rank historySep 2026 · #1 Clinical softwareFirst edition: no movements yet.

Estimated valuation

AI · Clinical software ranking (worldwide)

≈ USD 15bnUSD 12–19bn · Decacorn High confidence

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Anchor: Last known equity round: Equity round · USD 250M · Sep 2026
Published valuation: USD 15bn · Sep 2026

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

Date	Round	Amount	Type	Investors	Source
Sep 2026	Equity round	USD 250M	Equity	Andreessen Horowitz, Byers Capital	beckershospitalreview.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of OpenEvidence as a PDF, on one of three angles only:

ValuationWhat is OpenEvidence worth?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Invest

OpenEvidence is not open to Backers. A company opens only when a shareholder plans to sell or the company plans to raise.

Back the market instead: your intention joins a pool, passed to the local partner once it reaches critical mass.

Declare an interest in clinical software Name OpenEvidence as a preferred company (measures demand, promises nothing)

Clinical software poolBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until its pool is passed on. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run OpenEvidence?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round. Claiming never changes the rank.

Claim this profile Report an upcoming round →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Press & investor announcements4 sources

Read by the AI at the next edition.

Comparable companies in clinical software

Full clinical software ranking →

Commure#2United StatesUnicorn Abridge#3United StatesUnicorn Innovaccer#4United StatesUnicorn Hippocratic AI#5United StatesUnicorn

Investors in OpenEvidence: Andreessen Horowitz · Byers Capital

Sources. beckershospitalreview.com · statnews.com · en.wikipedia.org · aiweekly.co

Last updated: Sep 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.